BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 63 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,749 | -1.5% | 79,000 | 0.0% | 0.00% | – |
| Q2 2023 | $77,902 | -3.9% | 79,000 | 0.0% | 0.00% | – |
| Q1 2023 | $81,050 | -86.8% | 79,000 | -86.3% | 0.00% | -100.0% |
| Q4 2022 | $612,712 | -1.2% | 575,000 | -8.0% | 0.00% | 0.0% |
| Q3 2022 | $620,000 | -9.4% | 625,000 | -9.3% | 0.00% | 0.0% |
| Q2 2022 | $684,000 | -31.7% | 689,000 | -30.9% | 0.00% | -50.0% |
| Q1 2022 | $1,002,000 | -21.7% | 997,000 | -17.9% | 0.00% | 0.0% |
| Q4 2021 | $1,280,000 | +48.3% | 1,214,000 | +45.2% | 0.00% | +100.0% |
| Q3 2021 | $863,000 | +9.4% | 836,000 | +10.6% | 0.00% | 0.0% |
| Q2 2021 | $789,000 | -64.3% | 756,000 | -65.6% | 0.00% | -75.0% |
| Q4 2017 | $2,207,000 | +81.3% | 2,200,000 | +83.3% | 0.00% | +100.0% |
| Q3 2017 | $1,217,000 | – | 1,200,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |